MacroGenics' Margenza (margetuximab-cmkb) Receives the US FDA's Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Shots:
- The approval is based on P-III SOPHIA trial involves assessing of Margenza (IV- 15 mg/kg- q3w) vs Herceptin (trastuzumab- IV- 6mg/kg or 8mg/kg for loading dose) both combined with CT in 536 patients in a ratio (1:1) with HER2-positive m-BC who have received two or more prior anti-HER2 regimens- at least one of which was for metastatic disease.
- The study showed 24% reduction in the risk of disease progression or death- ORR (22% vs 16%)- The final OS analysis is expected in the H2’21
- Margenza is an Fc-engineered- mAb that targets the HER2 oncoprotein- also being evaluated in multiple trials for HER2+ gastroesophageal cancer & various HER2+ tumors
Ref: GLOBE NEWSWIRE | Image: Sign Builder Illustrated
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com